[ad_1]
Delhi, Feb. 10, 2022 (GLOBE NEWSWIRE) — Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
The advancement in the field of biotechnology and the robust research and development activities has led to the introduction of next generation antibodies which are designed to be more potent and specific than conventional monoclonal antibodies. The novel bispecific antibody constructs have unique ability to bind to two different targets at the same time. The advent of bispecific antibody constructs has shown several advantages over monoclonal antibodies in terms of efficacy, specificity, and size. To date, four bispecific antibodies have gained entry into the market.
Vabysmo (Faricimab) developed by Roche is a novel bispecific antibody which is approved in 2022 …
Full story available on Benzinga.com
[ad_2]
Source link
